The Centre Hospitalier Universitaire de Lille
Welcome,         Profile    Billing    Logout  
 0 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MANIER, Salomon
IsAMYP, NCT05066607: Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy

Recruiting
2
46
Europe
Isatuximab, Pomalidomide, Dexamethasone
Intergroupe Francophone du Myelome, Sanofi, Bristol-Myers Squibb
AL Amyloidosis
03/26
03/26
IFM 2021-01, NCT05572229: Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Recruiting
2
74
Europe
Teclistamab, JNJ-64007957, Daratumumab, Lenalidomide
University Hospital, Lille, Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
05/25
09/30
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
NCT04643002 / 2020-003024-16: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting
1/2
258
Europe, US, RoW
Isatuximab, SAR650984, Sarclisa®, Dexamethasone, Pomalidomide, Pomalyst®, Belantamab mafodotin, BLENREP®, Pegenzileukin, SAR444245, SAR439459, Belumosudil, SAR445761,, Rezurock, Evorpacept, ALX148
Sanofi
Plasma Cell Myeloma Refractory
07/27
03/28
MK-4002-001, NCT04184050 / 2019-004793-26: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002

Checkmark Data from trial for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for multiple myeloma at ASH 2022
Checkmark Data from trial for r/r multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022
Checkmark Data from trial for multiple myeloma at ASH 2021
More
Active, not recruiting
1
100
Europe, US
MK-4002, HPN217
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
06/25
11/25
NCT03309111: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Completed
1
81
Europe, US
ISB 1342
Ichnos Sciences SA, Glenmark Pharmaceuticals S.A.
Relapsed/Refractory Multiple Myeloma
12/23
12/23
NCT04887259 / 2020-004583-26: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Checkmark Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Efficacy data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Dec 2022 - Dec 2022: Safety data from trial for r/r CD1d-positive CLL, multiple myeloma, or AML at ASH 2022
Checkmark First patient dosing for P1/2a for relapsed refractory CLL
More
Terminated
1
16
Europe, US
LAVA-051, Interleukin 2
Lava Therapeutics, LAVA Therapeutics N.V., LAVA Therapeutics B.V.
Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
09/23
09/23
KTX-MMSET-001, NCT05651932: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Recruiting
1
125
Europe, Canada, US
Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide
K36 Therapeutics, Inc.
Multiple Myeloma, Myeloma, Myeloma Multiple
12/25
06/26
Covimmunomm, NCT04805203: Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma

Terminated
N/A
139
Europe
blood sample analyses
Intergroupe Francophone du Myelome
Multiple Myeloma, Covid19
12/22
12/22
TEC-CARE, NCT06062537: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Recruiting
N/A
200
Europe
Intergroupe Francophone du Myelome, Janssen-Cilag Ltd.
Multiple Myeloma
09/26
09/26

Download Options